Tremfya
(Guselkumab)ApprovedMonoclonal antibody
Johnson & JohnsonGuselkumab is used to treat moderate to severe plaque psoriasis, a skin condition that causes red, itchy, scaly patches on the skin.[2] Tremfya is currently approved and in use across 38 indications[4].[1]
Tremfya is one of 565 monoclonal antibody programs targeting Pyoderma Gangrenosum. It is currently in Approved.
38
Indications
91
Total Trials
44
Active Trials
564
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 38 indications
Competition
Competitive Landscape
1050 competitors in Asthma
#DrugCompanyPhaseTrials
1Tremfya
Johnson & JohnsonApproved
Veramyst
GSKPreclinical
Asmanex
NovartisPreclinical
Celexa
AbbViePreclinical
Atrovent
Boehringer IngelheimPreclinical
Symbicort
AstraZenecaPreclinical
Atrovent
Boehringer IngelheimPreclinical
Aciphex
Akero TherapeuticsPreclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Tylenol
KKenvue Brands
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Psoriasis19 trials
Show 16 more trials
Crohn's Disease11 trials
Show 8 more trials
Guselkumab Vs Ustekinumab in Stricturing Crohn's Disease
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University··NCT07444060·100 enrolled
Psoriatic Arthritis7 trials
Show 4 more trials
Arthritis, Psoriatic5 trials
Show 2 more trials
Colitis, Ulcerative4 trials
36 more indications
Hidradenitis Suppurativa3 trials
Crohn Disease3 trials
Ulcerative Colitis2 trials
Intravenous2 trials
Familial adenomatous polyposis2 trials
Liver2 trials
Intravenous Administration1 trial
Inflammatory Bowel Disease1 trial
Pain Perception1 trial
NAFLD1 trial
ART1 trial
Giant Cell Arteritis1 trial
Generalized Pustular Psoriasis1 trial
Palmoplantar Pustulosis1 trial
Pustular Psoriasis1 trial
MPA1 trial
Contact Dermatitis1 trial
Autoimmune Disease1 trial
Liver Disease1 trial
Observational Study1 trial
Inflammatory Bowel Disease (IBD)1 trial
Rheumatic Disease1 trial
Fistulizing Crohns Disease1 trial
Crohn Disease (CD)1 trial
Optimal Care With Guselkumab In Crohn's Disease
Recruiting·GGroupe d'Etude Therapeutique des Affections Inflammatoires Digestives·Approved·NCT07616687·210 enrolled
Plaque Psoriasis1 trial
Hailey-Hailey disease1 trial
Unspecified2 trials
Real-Life Evaluation of Guselkumab Dosing Interval Adjustments
Recruiting·—··NCT07430319·100 enrolled
Regulatory
FDA Approval Timeline[5]
Jul 13, 2017
TREMFYA
BLA BLA761061
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Tremfya drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Guselkumab. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Il-23p19 Inhibitor[3]
- Modality
- Monoclonal antibody[3]
- Highest Phase
- Approved[1]
- Company